Halozyme Therapeutics, Inc.
$109.68
$1.24 (+1.14%)
$106.82Day Range$110.88
Key Statistics
Market Cap
$12.31B
Shares Outstanding
113.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 12, 2004
Round Lot
100
Locale
US
Trading Data
Day Open
$107.08
Day High
$110.88
Day Low
$106.82
Volume
1.98M
VWAP
$109.27
Prev Close
$108.44
Transactions
--
Acc. Volume
--
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836423 employees12390 EL CAMINO REAL, SAN DIEGO, CA, 92130(858) 794-8889IPO Mar 12, 2004US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001159036
- Composite FIGI
- BBG000CZ8W54
- Share Class FIGI
- BBG001SGX585
- Ticker Root
- HALO
- SIC Code
- 2836
About Halozyme Therapeutics, Inc. (HALO) Stock
Halozyme Therapeutics, Inc. (HALO) closed the 2026-09-17 session at $109.68, up 1.14% versus the previous close (+1.24). The stock opened at $107.08 and traded between $106.82 and $110.88 during that session. Session trading volume was 2.0M shares. The volume-weighted average price (VWAP) is $109.27.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Halozyme Therapeutics, Inc. has a market capitalization of $12.31 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. HALO is listed on the XNAS exchange. The company employs approximately 423 people. Halozyme Therapeutics, Inc. is headquartered in SAN DIEGO, CA. The recorded listing date is 2004-03-12.
On this page you can find market HALO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.